389 related articles for article (PubMed ID: 30122516)
1. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
2. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
[TBL] [Abstract][Full Text] [Related]
3. Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy.
Mizutani K; Horie K; Kato T; Nakane K; Kawakami K; Fujita Y; Ito M
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1661-1663. PubMed ID: 30515569
[No Abstract] [Full Text] [Related]
4. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous ablative cryoimmunotherapy for micrometastaic abscopal effect: No complications.
Soule E; Bandyk M; Matteo J
Cryobiology; 2018 Jun; 82():22-26. PubMed ID: 29680230
[TBL] [Abstract][Full Text] [Related]
6. Kidney cancer in 2017: Challenging and refining treatment paradigms.
Ball MW; Srinivasan R
Nat Rev Urol; 2018 Feb; 15(2):77-78. PubMed ID: 29335524
[No Abstract] [Full Text] [Related]
7. Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor.
El Mouallem N; Smith SC; Paul AK
J Oncol Pract; 2018 Aug; 14(8):511-513. PubMed ID: 29920137
[No Abstract] [Full Text] [Related]
8. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
Schmidinger M
Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment.
Tabei T; Natsume I; Kobayashi K
Int J Urol; 2017 Sep; 24(9):708-710. PubMed ID: 28734029
[TBL] [Abstract][Full Text] [Related]
10. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
11. Updates to the Management of Kidney Cancer.
Jonasch E
J Natl Compr Canc Netw; 2018 May; 16(5S):639-641. PubMed ID: 29784745
[TBL] [Abstract][Full Text] [Related]
12. Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy.
Wynja E; Solomon B; Bleeker J
J Immunother; 2018 Sep; 41(7):340-342. PubMed ID: 29965859
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.
Rebuzzi SE; Bregni G; Grassi M; Damiani A; Buscaglia M; Buti S; Fornarini G
Immunotherapy; 2018 Sep; 10(13):1123-1132. PubMed ID: 30236027
[TBL] [Abstract][Full Text] [Related]
14. Role of immunotherapy in kidney cancer.
Nazzani S; Bazinet A; Karakiewicz PI
Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
[TBL] [Abstract][Full Text] [Related]
15. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma.
Xie G; Gu D; Zhang L; Chen S; Wu D
Cancer Biol Ther; 2017 Aug; 18(8):547-551. PubMed ID: 28665741
[TBL] [Abstract][Full Text] [Related]
16. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
18. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
[TBL] [Abstract][Full Text] [Related]
19. Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer.
Desideri I; Francolini G; Scotti V; Pezzulla D; Becherini C; Terziani F; Delli Paoli C; Olmetto E; Visani L; Meattini I; Greto D; Bonomo P; Loi M; Detti B; Livi L
Clin Transl Oncol; 2019 Jul; 21(7):933-938. PubMed ID: 30565084
[TBL] [Abstract][Full Text] [Related]
20. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.
Lattanzi M; Deng FM; Chiriboga LA; Femia AN; Meehan SA; Iyer G; Voss MH; Sundatova Y; Huang WC; Balar AV
J Immunother Cancer; 2018 Oct; 6(1):97. PubMed ID: 30285856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
